RegulatoryJun 15, 2026, 08:02 AM
AIM ImmunoTech Regains NYSE American Listing Compliance
AI Summary
AIM ImmunoTech Inc. announced it has regained compliance with NYSE American's continued listing standards related to stockholders' equity. This achievement follows a series of financing activities in May and June 2026, including a warrant exercise inducement offer and the issuance of common stock and warrants, which collectively raised approximately $8.5 million. The company now believes its stockholders' equity exceeds the $6.0 million minimum requirement, leading to the removal of the "below compliance" indicator from its trading symbol.
Key Highlights
- AIM ImmunoTech regained compliance with NYSE American's continued listing standards for stockholders' equity.
- The company's stockholders' equity now exceeds the $6.0 million minimum requirement.
- A warrant exercise inducement offer generated approximately $3.5 million in gross proceeds.
- Issued 7,519,351 common shares and Class I warrants for approximately $2.4 million.
- Issued 2,554,119 common shares, pre-funded warrants, and Class J warrants for approximately $2.6 million.
- NYSE American confirmed resolution of Sections 1003(a)(i), (ii), and (iii) deficiencies.
- The ".BC" indicator will be removed from the Company's trading symbol.
Price Impact
More from AIM